Intangible Assets (Details Narrative)	Sep. 12, 2017 USD ($) shares
Health Canada Natural Product [Member]
Common stock shares issued, shares	2,500,000
License Agreement [Member] | Solumer Oral Drug Delivery Technology [Member]
Financial considerations payable under licensing description	1) Monthly license fee until commercialization date (US$10,000); and2) Milestone payments upon commercialization (US$150,000) and upon net sales of US$5,000,000 (US$250,000). Other consideration includes royalties on aggregate net sales. In addition, the Company entered into a master formulations services agreement whereby the Company would be Formulex a monthly development fee of US$20,000. During the three months ended April 30, 2019, this master formulations services agreement was terminated.
Altum Pharmaceuticals Inc. [Member] | License Agreement [Member]
Common stock shares issued, shares	2,500,000
Common stock shares issued, amount | $	$ 319,174